# Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.

> **NCT00317161** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1000 (actual)

## Conditions studied

- Diphtheria
- Hepatitis B
- Haemophilus Influenzae Type b
- Whole Cell Pertussis
- Tetanus

## Interventions

- **BIOLOGICAL:** DTPw-HBV/Hib-MenAC conjugate vaccine

## Key facts

- **NCT ID:** NCT00317161
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317161, "Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00317161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*